YaoGeJu

← Back to list

Bimatoprost Eye Drops

Matched
Active ingredients (original)
BIMATOPROST
Dosage form (original)
SOLUTION/DROPS
Route (original)
OPHTHALMIC

Read these limits

  1. US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
  2. The Orange Book lists holder-submitted patents and does not cover all related patents.
  3. “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
  4. This page contains no sales or market-size data and cannot establish development value.
  5. Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.

US-approved products

Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.

Earliest approval2001/03/16
ANDA applications11
RLD applicantABBVIE INC

Currently marketed products: 10 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.

Application / product numberBrand name (original)Applicant (original)Dosage form (original)Route (original)Strength (original)Earliest approvalRLD / RSMarketing status (original)Official source
A090449-001BIMATOPROSTAPOTEX INCSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2015/07/20N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A202505-001BIMATOPROSTMICRO LABS LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2020/09/08N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A202565-001BIMATOPROSTSANDOZ INCSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2015/05/05N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A203299-001BIMATOPROSTHIKMA PHARMACEUTICALS USA INCSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2018/11/08N / NDISCONTINUEDopenFDA ↗
A203991-001BIMATOPROSTLUPIN LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2015/02/20N / NDISCONTINUEDopenFDA ↗
A205537-001BIMATOPROSTEUGIA PHARMA SPECIALITIES LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2022/10/06N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A207601-001BIMATOPROSTSOMERSET THERAPEUTICS LLCSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2019/06/19N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A210126-001BIMATOPROSTGLAND PHARMA LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2019/03/22N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A210263-001BIMATOPROSTALEMBIC PHARMACEUTICALS LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03%2019/04/12N / YHUMAN PRESCRIPTION DRUGopenFDA ↗
A217289-001BIMATOPROSTAMNEAL EU LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.01%2025/09/22N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
A218196-001BIMATOPROSTMANKIND PHARMA LTDSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.01%2025/03/17N / NHUMAN PRESCRIPTION DRUGopenFDA ↗
N021275-001LUMIGANABBVIE INCSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**2001/03/16Y / NDISCONTINUEDopenFDA ↗
N022184-001LUMIGANABBVIE INCSOLUTION/DROPSOPHTHALMICBIMATOPROST: 0.01%2010/08/31Y / YHUMAN PRESCRIPTION DRUGopenFDA ↗

Listed US patents

*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.

Latest listed patent expiration2027/06/13
Substance patent expiration (DS flag)2027/06/13

This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.

Application / product numberPatent numberListed expirationSubstance / product flagsUse codeDelisting requestOfficial source
N022184-00178515042027/06/13Y / Y——openFDA ↗

Exclusivity source records

FDA exclusivity code list ↗

Latest exclusivity expiration: —

Application / product numberExclusivity codeListed expirationOfficial source
Not listed

Chinese record details

Chinese product landscape ↗

The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Catalog holders 1

Company (original)Identifier (original)Source dateOfficial source
Allergan Inc.H201504855ml:1.5mg2005/04/20Official source ↗
Allergan Inc.H201504843mL:0.9mg2005/04/20Official source ↗

NHSA approval numbers 7

Company (original)Identifier (original)Source dateOfficial source
Beijing Bei Lu Pharma Co., Ltd. romanized国药准字H202660250.03%(3ml: 0.9mg)—Official source ↗
Hubei Yuan Da Tian Tian Ming Pharmaceutical Co., Ltd. romanized国药准字H202130690.03%(3ml:0.9mg)—Official source ↗
AbbVie Deutschland GmbH & Co. KG国药准字HJ201504843ml:0.9mg—Official source ↗
Zhao Ke (Guangzhou) Yan Ke Drug Co., Ltd. romanized国药准字H202448920.03%(0.4ml:0.12mg)—Official source ↗
Shandong Wei Zhi Bai Ke Pharma Co., Ltd. romanized国药准字H202441030.03%(3ml:0.9mg)—Official source ↗
Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized国药准字H202644720.03%(3ml:0.9mg)—Official source ↗
Zhao Ke (Guangzhou) Yan Ke Drug Co., Ltd. romanized国药准字H202448920.03%(0.4ml:0.12mg)—Official source ↗
Hainan Si Da Pharmaceutical Co., Ltd. romanized国药准字H202658820.03%(0.4ml:0.12mg)—Official source ↗
Hainan Si Da Pharmaceutical Co., Ltd. romanized国药准字H202658820.03%(0.4ml:0.12mg)—Official source ↗

Under review 3

Company (original)Identifier (original)Source dateOfficial source
Zhuhai Qian Lie Pharma Co., Ltd. romanized; HUNAN WARRANT PHARMACEUTICAL CO.,LTDCYHS26025552026/10/16Official source ↗
Zhuhai Qian Lie Pharma Co., Ltd. romanized; HUNAN WARRANT PHARMACEUTICAL CO.,LTDCYHS26025542026/10/16Official source ↗
Guangzhou Da Guang Pharmaceutical Co., Ltd. romanizedCYHS26009672026/04/27Official source ↗

Generic-filing companies this year 2

Company (original)Identifier (original)Source dateOfficial source
Zhuhai Qian Lie Pharma Co., Ltd. romanized; HUNAN WARRANT PHARMACEUTICAL CO.,LTDCYHS26025552026/10/16Official source ↗
Zhuhai Qian Lie Pharma Co., Ltd. romanized; HUNAN WARRANT PHARMACEUTICAL CO.,LTDCYHS26025542026/10/16Official source ↗
Guangzhou Da Guang Pharmaceutical Co., Ltd. romanizedCYHS26009672026/04/27Official source ↗

API companies with A status 6

Company (original)Identifier (original)Source dateOfficial source
Zhejiang Fu Nuo Pharmaceuticals Co., Ltd. romanizedY202500003942026/10/14Official source ↗
Taiwan Yong Guang Chemical Gong Ye Co., Ltd. Di Er Factory romanizedY202200008192025/01/26Official source ↗
YS Life Science Co., Ltd.Y202100009112024/06/05Official source ↗
Shen Long Pharmaceuticals (Chang Shu) Co., Ltd. romanizedY201900004952026/03/10Official source ↗
EUROAPI Hungary Ltd.Y201900004422026/10/30Official source ↗
Wuhan Wu Yao Pharmaceutical Co., Ltd. romanizedY201700002452023/07/04Official source ↗

Trial registrations 2025/2026 —

Not loaded

Sources and dates

FDA Orange Book
2026/11/06
CDE acceptance and review
2026/11/13 06:42
Chemical Drug Catalog
2026/11/13 06:39
API registration records
2026/11/13 06:41
NHSA drug code database
2026/10/23
Trial registry
2026/11/13 08:09 · Incomplete coverage

Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.

Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗

Name and dosage-form matching sources